Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors.

doi:10.1016/0014-2999(90)90174-5

Paper

DOI: 10.1016/0014-2999(90)90174-5

Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors.

Published Apr 25, 1990 · G. Mereu, G. Carcangiu, A. Concas

European journal of pharmacology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

Zolpidem has a more potent inhibitory action on substantia nigra pars reticulata neuron activity than anxiolytics alpidem and diazepam, likely through activation of benzodiazepine receptors.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1126/SCIENCE.2551039

Type I and type II GABAA-benzodiazepine receptors produced in transfected cells.

Diversity in benzodiazepine pharmacology is driven by heterogeneity of the alpha subunit of the GABAA receptor, with type I and type II receptor subtypes showing distinct pharmacological properties.

1989·725citations·D. B. Pritchett et al.·Science

Science

DOI: 10.1038/338582A0

Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology

The new GABAA receptor subunit 2 enhances benzodiazepine pharmacology by providing high-affinity binding sites for central benzodiazepine receptor ligands.

1989·1329citations·D. B. Pritchett et al.·Nature

Nature

DOI: 10.1016/0014-2999(89)90840-6

Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors.

Zolpidem enhances GABAergic transmission with a different efficacy than diazepam, suggesting it is a partial agonist at the benzodiazepine recognition site.

1989·51citations·G. Biggio et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1073/PNAS.85.20.7815

Mapping of brain areas containing RNA homologous to cDNAs encoding the alpha and beta subunits of the rat GABAA gamma-aminobutyrate receptor.

GABAA receptor gene expression in the rat brain shows regional heterogeneity, potentially reflecting differences in RNA stability, transcription rate, or subunit composition.

1988·105citations·J. Séquier et al.·Proceedings of the National Academy of Sciences of the United States of America

Proceedings of the National Academy of Sciences of the United States of America

DOI: 10.1016/s0022-3565(25)20029-5

Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem.

Omega 1 receptor subtypes are more abundant in sensorimotor cortical regions and extrapyramidal motor system, while omega 2 sites predominate in limbic areas.

1988·112citations·T. Dennis et al.·The Journal of pharmacology and experimental therapeutics

The Journal of pharmacology and experimental therapeutics

Citations

DOI: 10.1080/07391102.2021.1997818

Imidazopyridine, a promising scaffold with potential medicinal applications and structural activity relationship (SAR): recent advances

Imidazopyridines show potential as lead molecules for various therapeutic disorders, with recent advances in their design and structure-activity relationships.

2021·27citations·S. Khatun et al.·Journal of Biomolecular Structure and Dynamics

Journal of Biomolecular Structure and Dynamics

DOI: 10.1111/ejn.14075

Zolpidem ameliorates motor impairments in the unilaterally 6‐hydroxydopamine‐lesioned rat

Zolpidem improves motor coordination and volitional forelimb use in a Parkinson's disease rat model, suggesting it may be a novel therapeutic target for treating motor symptoms in Parkinson's disease.

2018·7citations·Robert Assini et al.·European Journal of Neuroscience

European Journal of Neuroscience

DOI: 10.1021/jo201273p

Reaction of β-lactam carbenes with 2-pyridyl isonitriles: a one-pot synthesis of 2-carbonyl-3-(pyridylamino)imidazo[1,2-a]pyridines useful as fluorescent probes for mercury ion.

This one-pot synthesis of 2-carbonyl-3-(pyridylamino)imidazo[1,2-a]pyridines produces efficient fluorescent probes for mercury ion in acetonitrile and buffered aqueous solutions.

2011·98citations·N. Shao et al.·The Journal of organic chemistry

The Journal of organic chemistry

DOI: 10.1039/C1SC00122A

Asymmetric organocatalytic [3 + 2]-annulation strategy for the synthesis of N-fused heteroaromatic compounds

This organocatalytic strategy efficiently synthesizes N-fused heteroaromatic compounds with high enantioselectivity, broad substrate scope, operational simplicity, and low catalyst loadings.

2011·51citations·Ł. Albrecht et al.·Chemical Science

Chemical Science

DOI: 10.1007/s11030-008-9072-1

Emerging approaches for the syntheses of bicyclic imidazo[1,2-x]-heterocycles

High-throughput methodologies have enabled the rapid syntheses of bicyclic imidazo[1,2-x]-heterocycles, which have potential for discovery and development of new molecular therapeutics.

2008·83citations·C. Hulme et al.·Molecular Diversity

Molecular Diversity

DOI: 10.1111/j.1745-7254.2008.00735.x

Modulation of synaptic GABAA receptor function by zolpidem in substantia nigra pars reticulata

Zolpidem significantly potentiates GABA currents and inhibits the activity of the substantia nigra pars reticulata, potentially offering potential treatment for basal ganglia disorders.

2008·26citations·Li-li Zhang et al.·Acta Pharmacologica Sinica

Acta Pharmacologica Sinica

DOI: 10.1055/s-2007-1017838

Neue Schlafmittel: Zopiclon und Zolpidem

Zopiclone and zolpidem effectively reduce sleep onset latency, duration, and awakenings in insomniac patients, but may have some psychological side effects and potential tolerance/dependency.

1996·2citations·P. Clarenbach·Aktuelle Neurologie

Aktuelle Neurologie

DOI: 10.1055/s-2007-1014298

Zolpidem and Rebound Insomnia - A Double-Blind, Controlled Polysomnographic Study in Chronic Insomniac Patients

Zolpidem does not induce rebound insomnia or daytime anxiety after long-term treatment for chronic insomniac patients.

1994·1citation·J. Monti1 et al.·Pharmacopsychiatry

Pharmacopsychiatry